Significant potential of melatonin therapy in Parkinson's disease - a meta-analysis of randomized controlled trials.

ABSTRACT:

Objective

Since its discovery as an antioxidant, melatonin has been increasingly recognized for its therapeutic potential beyond sleep disturbances in neurodegenerative disorders. This study aims to evaluate efficacy of various melatonin doses, treatment durations, and formulations, in alleviating motor symptoms and sleep disturbances in Parkinson's disease, the second most common neurodegenerative disorder worldwide.

Methods

PubMed, Cochrane Library, ClinicalTrials.gov and other databases were systematically searched to retrieve randomized controlled trials (RCTs) administrating melatonin to Parkinson's disease patients until June 10th, 2023. Outcomes including Unified Parkinson Disease Rating Scale (UPDRS) scores and Pittsburgh Sleep Quality Index (PSQI) scores, were poole

SUBMITTER: Iftikhar S 

PROVIDER: S-EPMC10597669 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature